HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
Lyt antibodies
Also Known As:
Lyt molecules; alphaLyt-1; alphaLyt-2; anti-Lyt 1.2 antibody; anti-Lyt 2.2 antibody; anti-Lyt-1; anti-Lyt-2
Networked:
28
relevant articles (
1
outcomes,
0
trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Amino Acids, Peptides, and Proteins: 1
Proteins: 484843
Blood Proteins: 12459
Serum Globulins: 553
Immunoglobulins: 30480
Antibodies: 133716
Isoantibodies: 806
Lyt antibodies: 28
Immunoproteins: 43
Immunoglobulins: 30480
Antibodies: 133716
Isoantibodies: 806
Lyt antibodies: 28
Globulins: 3062
Serum Globulins: 553
Immunoglobulins: 30480
Antibodies: 133716
Isoantibodies: 806
Lyt antibodies: 28
Related Diseases
1.
Demyelinating Diseases (Demyelinating Disease)
05/01/1988 - "
Successful therapy of Theiler's virus-induced demyelination (DA strain) with monoclonal anti-Lyt-2 antibody.
"
04/15/1989 - "
In an attempt to better understand the role of the immune response during demyelination, mononuclear leukocytes were isolated from the central nervous system of infected mice and stained by an immunoperoxidase technique with anti-Thy-1.2, anti-L3T4, anti-Lyt-2 and anti-MAC-1 mAb. Infection of susceptible SJL/J mice resulted in a biphasic immune response which peaked on days 7 and 27 post-infection.
"
2.
Neoplasms (Cancer)
08/15/1989 - "
Specifically, depletion of Lyt 2+ T-cells from mice bearing a large MOPC-315 tumor by treatment with monoclonal anti-Lyt 2.2 antibody abolished the curative effectiveness of the low dose of drug.
"
12/01/1988 - "
Tumor regression was mediated by tumor-sensitized Lyt2+ T cells, as evidenced by the finding that treatment of tumor-bearing mice with anti-Lyt-2 mAb alone, or in combination with anti-L3T4 mAb, resulted in enhancement of tumor growth and a significant decrease in host survival time.
"
04/01/1984 - "
Lymphocytes derived from various host lymphoid organs as well as from the tumor site were labeled either directly with 125I-conjugated monoclonal anti-Lyt antibodies or by a sandwich labeling technique with monoclonal anti-Lyt antibodies and 125I-conjugated anti-mouse Ig.
"
02/01/1986 - "
Treatment of these lymphoid cells with anti-Thy-1.2 or anti-Lyt antibodies plus complement revealed that the in vivo anti-tumor immune responses were mediated predominantly by a Lyt-1+2- T cell subset.
"
11/01/1984 - "
Removal of the suppressive activity of spleen cells from UVB-irradiated mice through the use of monoclonal anti-Lyt-1 antibodies resulted in a population of cells capable of mediating tumor rejection when injected into lethally x-irradiated recipients.
"
3.
Infections
10/01/1992 - "
The splenic colonization on Day 6 after challenge demonstrated that treatment with anti-Lyt-2 mAb impaired resistance against a subsequent infection with C.
"
10/01/1992 - "
One month after primary infection, mice were treated with anti-L3T4 or anti-Lyt-2 mAb and challenged thereafter (i.v., 1 x 10(5) PFU).
"
09/15/1987 - "
The course of infection after injection of small doses of bacillus Calmette-Guérin (BCG) was studied in mice which were depleted in vivo of T cell subsets by administration of either anti-L3T4 or anti-Lyt-2 mAb. The results presented herein strongly suggest that the L3T4+ subpopulation play a pivotal role in the immunologic control of BCG infection because the depletion of L3T4+ cells led to a dramatic increase in the number of viable bacteria.
"
04/01/1987 - "
In mice treated with anti-Lyt-2, induction of cytotoxic T cells was reduced to less than 1 to 2% after intravenous infection with Armstrong strain of lymphocytic choriomeningitis virus (LCMV).
"
04/15/1989 - "
In an attempt to better understand the role of the immune response during demyelination, mononuclear leukocytes were isolated from the central nervous system of infected mice and stained by an immunoperoxidase technique with anti-Thy-1.2, anti-L3T4, anti-Lyt-2 and anti-MAC-1 mAb. Infection of susceptible SJL/J mice resulted in a biphasic immune response which peaked on days 7 and 27 post-infection.
"
4.
Hypersensitivity (Allergy)
09/01/1990 - "
Listeria-infected mice that had been treated with anti-Lyt-2 mAb alone developed a strong delayed-type hypersensitivity (DTH) response, although it was significantly reduced as compared to control listeria-infected mice.
"
02/01/1989 - "
In vivo selective T cell depletion by anti-L3T4 or anti-Lyt-2 mAb allowed us to demonstrate the predominant role of Lyt-2+ cells in protection and that of L3T4+ cells in the expression of delayed-type hypersensitivity.
"
08/01/1988 - "
Delayed-type hypersensitivity (DTH) to listerial antigen was totally abolished in mice treated with anti-Thy-1.2 or anti-L3T4 MAbs, whereas anti-Lyt-2 MAb treatment had no effect, regardless of whether the MAb was given during the induction or the expression of DTH.
"
09/01/1990 - "
Effects of purified anti-Lyt-2 mAb treatment on murine listeriosis: comparative roles of Lyt-2+ and L3T4+ cells in resistance to primary and secondary infection, delayed-type hypersensitivity and adoptive transfer of resistance.
"
5.
Coinfection
08/01/1988 - "
On the other hand, the elimination of bacteria from the spleens of infected animals was inhibited only by the application of either anti-Thy-1.2 MAb or anti-Lyt-2 MAb. This could be shown most impressively during the secondary infection of immune mice with a normally lethal dose of listeriae.
"
09/01/1990 - "
Effects of purified anti-Lyt-2 mAb treatment on murine listeriosis: comparative roles of Lyt-2+ and L3T4+ cells in resistance to primary and secondary infection, delayed-type hypersensitivity and adoptive transfer of resistance.
"
Related Drugs and Biologics
1.
Lyt antibodies
2.
Antibodies
3.
Complement System Proteins (Complement)
4.
Monoclonal Antibodies
5.
Antigens
6.
anti-Thy antibody
7.
Cytostatic Agents
8.
Synthetic Vaccines (Recombinant Vaccines)
9.
Trehalose
10.
Nylons (Nylon)
Related Therapies and Procedures
1.
Therapeutics
2.
Transplantation
3.
Immunotherapy
4.
Drug Therapy (Chemotherapy)
5.
Aftercare (After-Treatment)